Oncotarget is a peer-reviewed medical journal with open access. The journal covers research on all the areas of oncology. Started in 2012, Oncotarget is published by the Impact Journals and posts papers and issues every week. Andrei Gudkov and Mikhail Blagosklonny serve as the Editors-in-Chief at Oncotarget and both of them also work at the Roswell Park Cancer Institute. Oncotarget is indexed and abstracted in Science Citation Index, Scopus, BIOSIS Previews and Index Medicus. As of 2016, the medical journal had an impact factor of 5.168 according to Journal Citation Reports. Oncotarget has a reputation the world over for its reliability and effectiveness on covering oncology research.
Oncology has over the years experienced a rising popularity because of its constructive, insightful, multiple peer-review approach. The medical journal helps its authors to increase their research impact. Due to its success in oncology, Oncotarget has started accepting papers on other topics besides oncology. These topics include Endocrinology, Chromosome, Microbiology and Immunology Cell Biology, Autophagy and Cell Death, metabolism, cardiology, Pharmacology, Neuroscience and many others. The term Oncotarget includes all cellular functions, molecules and pathways common in aging and cancer, lymphocytes and neurons, neurodegeneration and atherosclerosis, microbes as well as cancer cells. Visit Oncotarget’s profile page at Facebook.
A multidisciplinary traditional journal, Oncotarget allows readers to print any paper or issue in cases of special demand. The Ultimate goal of Oncotarget is to avail scientific results widely and rapidly. The medical journal also aims to use insightful review in order to maximize research impact. Oncotarget allows quick sharing of exceptional discoveries and aims to eliminate the border existing between specialties. Oncotarget works towards linking different biomedical science sectors and fostering applications of both basic and clinical science in conquering disease.
Oncotarget hopes to create a world without disease and has assisted many researchers in contributing to the science progress. Since its inception, Oncotarget has been able to publish more than 250 issues and papers regarding Oncology. Under the leadership of skilled and experienced scientists, Oncotarget has been able to register massive success and expansion. The Editorial Board of Oncotarget consists of researchers who are skilled, experienced and committed to contribute to the progress of science.